Opening book details…
Can I read Orelabrutinib: First Approval on EtoBox?
Orelabrutinib: First Approval by Sohita Dhillon is a Medicine article available to read on EtoBox.
What is Orelabrutinib: First Approval about?
Dysregulation of Bruton's tyrosine kinase (BTK) signalling has been linked to various B cell malignancies and autoimmune diseases. Orelabrutinib (宜诺凯 ® ) is an orally administered, potent, irreversible and highly selective BTK-inhibitor being developed by InnoCare Pharma for the treatment of B cell malignancies and autoimmune diseases. In December 2020, orelabrutinib received its first approval in China for the treatment of patients with mantle cell lymphoma (MCL) or chronic lymphocytic leukaemia (CLL)/small lymphocytic lymphoma (SLL), who have received at least one treatment in the past. Clinical development of orelabrutinib for various indications is underway in the USA and China. This article summarizes the milestones in the development of orelabrutinib leading to this first approval. Digital Features for this AdisInsight Report can be found at https :// doi.org/10.6084/m9.figsh are.14035
Who reads Orelabrutinib: First Approval?
It is typically read by researchers, students, and practitioners in Medicine.
- Author
- Sohita Dhillon
- Publisher
- Springer Science and Business Media LLC
- Published
- 2021
- Language
- EN
- Field
- Medicine (Health Sciences)